Setting up Sandoz for success as an independent listed company

2023 was an exceptional year for Sandoz, Europe’s largest generic and biosimilar medicines company and a brand with nearly 140 years of heritage. Sandoz’ USD 11.2bn spin-off from Novartis in October was one of the most closely watched European business stories of 2023, generating over 10,000 pieces of coverage. It created the biggest new entrant on the Swiss stock market since 2019 and was the largest listing in Europe of the year.

Successfully launching an independent Sandoz required strong collaboration with Sandoz Senior Leadership Team, Investor Relations, and across all aspects of internal and external communications – creating and delivering a fully integrated and carefully calibrated communications campaign. In a complex and often challenging environment, the communications strategy aimed to amplify the Sandoz strategy and equity story among media and investors, raise awareness of Sandoz among senior public affairs audience, and ensure Sandoz employees could successfully navigate the separation from Novartis. 

 Utilising in-depth CEO interviews with key financial publications and the launch of the refreshed Sandoz brand and Sandoz.com website, to highly targeted print and social media campaigns as well as extensive internal communications, it’s a story that underlines the importance of communications excellence at a definitive moment for the business.